RETA Stock News

NEW YORK--(BUSINESS WIRE)--Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of the securities of Reata Pharmaceuticals, Inc. (N

LOS ANGELES--(BUSINESS WIRE)---- $RETA #RETA--SHAREHOLDER ACTION REMINDER: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Reata Pharmaceuticals, Inc.

LOS ANGELES--(BUSINESS WIRE)---- $RETA #RETA--SHAREHOLDER ACTION ALERT: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Reata Pharmaceuticals, Inc.

NEW YORK, Oct. 15, 2020 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Reata Pharmaceuticals, Inc. ("Reata" or the "Company") (NASDAQ: RETA) and certain of

PLANO, Texas, Oct. 15, 2020 (GLOBE NEWSWIRE) -- Reata Pharmaceuticals, Inc. (“Reata” or “the Company” or “we”) announced today the upcoming presentation of K ID NEYCODE: A Genetic Testing

Reata Pharmaceuticals, Inc. (RETA) reported earnings 30 days ago.

PLANO, Texas, Sept. 03, 2020 (GLOBE NEWSWIRE) -- Reata Pharmaceuticals, Inc. (Nasdaq: RETA) (“Reata,” the “Company,” or “we”), a clinical-stage biopharmaceutical company, today announced

Reata (RETA) gets FDA recommendation to initiate a second study on omaveloxolone for additional data.

Reata Slips On Update And Other News: The Good, Bad And Ugly Of Biopharma

Reata Pharmaceuticals, Inc. (RETA) CEO Warren Huff on Q2 2020 Results - Earnings Call Transcript

The clinical-stage drug company may not be able to file for FDA approval of a top candidate as soon as expected.

Reata Pharmaceuticals, Inc. (RETA) delivered earnings and revenue surprises of 8.56% and 111.93%, respectively, for the quarter ended June 2020.

Shares of Reata Pharmaceuticals (NASDAQ:RETA) were unchanged after the company reported Q2 results.

PRE-NDA (NEW DRUG APPLICATION) MEETING GRANTED FOR BARDOXOLONE

Let us take a look at five small biotech companies, NVAX, ICPT, FOLD, RETA, HALO, which are gearing up for their earnings release.